Koenimbine has been researched along with Breast Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arun, A; Chourasia, MK; Karade, SS; Konwar, R; Patel, OPS; Saini, D; Singh, PK; Yadav, PP | 1 |
Ahmadipour, F; Arya, A; Fani, S; Firoozi, M; Kamalidehghan, B; Keong, YS; Looi, CY; Mohan, S; Noordin, MI; Paydar, M; Siyamak, EN; Sukari, MA; Yong, CL | 1 |
2 other study(ies) available for Koenimbine and Breast Neoplasms
Article | Year |
---|---|
Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt/mTOR in breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carbazoles; Caspases; Cell Line, Tumor; Down-Regulation; Humans; Inhibitory Concentration 50; PC-3 Cells; Polymerization; Proto-Oncogene Proteins c-akt; Pyrans; Rats; TOR Serine-Threonine Kinases; Tubulin | 2019 |
Koenimbin, a natural dietary compound of Murraya koenigii (L) Spreng: inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44(+)/CD24(-/low)): an in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Biomarkers, Tumor; Breast Neoplasms; Carbazoles; CD24 Antigen; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hyaluronan Receptors; MCF-7 Cells; Murraya; Neoplastic Stem Cells; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |